About Shape Therapeutics
Shape Therapeutics specializes in programmable RNA medicine, using artificial intelligence to analyze large datasets for new treatment development. Their technology, RNAfix, modifies RNA instructions to correct genetic mutations without changing DNA, while smart-sensing vector designs allow for tailored gene expression in specific cell types. The company aims to create effective and safe medicines that address the root causes of diseases, distinguishing itself by combining AI with RNA-based therapies.
Seattle, WashingtonHeadquarters
2018Year Founded
$143.5MTotal Funding
SERIES_BCompany Stage
AI & Machine Learning, BiotechnologyIndustries
51-200Employees
Risks
Intellectual property disputes may arise in the competitive RNA therapy field.
Regulatory challenges due to rapid AI and RNA advancements could impact ShapeTX.
Talent war in biotech may lead to recruitment challenges for ShapeTX.
Differentiation
ShapeTX uses AI to design novel RNAs for precise gene therapy.
Their RNAfix technology corrects RNA without altering DNA, offering unique therapeutic potential.
Smart-sensing vector designs enable tailored gene expression, surpassing first-generation gene therapies.
Upsides
Increased interest in RNA therapies boosts ShapeTX's market potential.
AI integration in drug discovery enhances ShapeTX's innovative capabilities.
FDA fast-tracking of RNA therapies supports ShapeTX's regulatory pathway.
Funding
Total raised$143.48 M
Latest valuation$560.00 M
StageSERIES_B
SERIES B
6/30/2021$112
$560.00 MSERIES A
10/31/2019$36
$177.50 M